Therapy of solid tumors using probiotic Symbioflor-2 – restraints and potential

To date, virulent bacteria remain the basis of most bacteria mediated cancer therapies. For clinical application attenuation is required. However, this might result in a drastically lowered therapeutic capacity. Herein we argue that the E. coli probiotic Symbioflor-2, with a history of safe applicat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kocijancic, Dino, Felgner, Sebastian, Frahm, Michael, Komoll, Ronja-Melinda, Iljazovic, Aida, Pawar, Vinay, Rohde, Manfred, Heise, Ulrike, Zimmermann, Kurt, Gunzer, Florian, Hammer, Juliane, Crull, Katja, Leschner, Sara, Weiss, Siegfried
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008385/
https://www.ncbi.nlm.nih.gov/pubmed/26981777
http://dx.doi.org/10.18632/oncotarget.8027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008385/
https://www.ncbi.nlm.nih.gov/pubmed/26981777
http://dx.doi.org/10.18632/oncotarget.8027

Ejemplares similares